A common vitamin offers an unexpected research lead
Vitamin B12 may offer a new way to investigate treatments for Verheij syndrome, a rare genetic disorder associated with impaired growth and developmental delay. In laboratory experiments, researchers found that the vitamin largely reversed developmental abnormalities in worms carrying a mutation linked to the human condition.
The work does not establish a treatment for people, and the central experiments were conducted in the roundworm Caenorhabditis elegans. But the study also identified similar metabolic changes in human patients, providing a reason to investigate whether the finding could point toward therapies for rare disorders tied to disrupted RNA splicing.
That combination matters. Results in a laboratory model are often the beginning of a research path rather than the end of one. Here, the researchers report both a strong response in the model organism and evidence that the affected biological pathways may be relevant in people with the disorder.
From RNA splicing to developmental problems
The research centers on RNA splicing, a cellular process that helps prepare genetic instructions for protein production. Cells first produce messenger RNA, and splicing removes unnecessary sections before the remaining pieces are joined in the appropriate order. When the process is disrupted, essential cellular functions can be affected.
Mutations in genes involved in splicing can contribute to serious developmental disorders. Verheij syndrome is one such condition. It is associated with developmental delays, growth problems and short stature.
Scientists investigated a related mutation in C. elegans, a small roundworm widely used in biological research. The researchers had initially been looking for genes that influence lifespan when they began studying a mutation in a gene involved in RNA splicing. That same gene is associated with Verheij syndrome in humans.
The mutated worms developed abnormalities that mirrored important features of the human disorder. Their growth slowed and they remained smaller than unaffected worms. Those measurable effects gave the team a way to explore what the mutation was doing inside the organism and whether its consequences could be changed.
Metabolism provided the clue
To understand the growth defect, the researchers used genetic screens and metabolic analysis. They found that the mutation disrupted specific metabolic pathways that depend on vitamin B12. Those pathways are important for healthy growth and normal cellular activity.
They then tested whether additional vitamin B12 could counteract the disruption. The vitamin largely reversed the developmental defects observed in the worms. The result suggests that at least some effects of the splicing-linked mutation may arise through metabolic changes that are responsive to an available nutrient.
That is a significant conceptual shift from treating a genetic diagnosis as a fixed and untouchable cause. The mutation itself was not removed. Instead, the study points to the possibility that downstream effects of the mutation may be tractable. In this case, the downstream signal was a disturbance in B12-dependent metabolism.
The human relevance remains a central question. The study reports similar metabolic changes in patients with Verheij syndrome, but it does not show that vitamin B12 will safely or effectively correct clinical problems in people. Clinical research would be needed to answer whether supplementation, dosing or another intervention aimed at the same pathways could help patients.
Why the finding is still important
Rare genetic disorders can be especially difficult to study because they affect relatively small patient populations and may involve fundamental processes shared by many cells. Model organisms can help researchers identify mechanisms quickly, then focus subsequent work on the most plausible pathways in human samples and clinical studies.
The new finding illustrates the value of that approach. A worm model revealed a developmental phenotype, metabolic analysis identified a candidate vulnerability, and vitamin B12 produced a substantial rescue in the model. Observing related metabolic changes in human patients strengthens the case for further investigation without eliminating the need for careful translation.
Vitamin B12 is common, but that should not be mistaken for proof of a ready-made therapy. A promising result in C. elegans is not a treatment recommendation for people with Verheij syndrome. The practical importance of the study is that it identifies a testable biological direction: B12-dependent metabolism may be part of the chain linking a splicing mutation to developmental abnormalities.
What the researchers found
- A mutation associated with Verheij syndrome caused slowed growth and smaller body size in C. elegans.
- The mutation disrupted metabolic pathways that depend on vitamin B12.
- Additional vitamin B12 largely reversed developmental abnormalities in the worm model.
- Similar metabolic changes were identified in human patients.
- Further research is required before the finding can be considered a treatment for people.
The next research question
The key next step is to determine how closely the worm response maps onto human biology. Researchers will need to establish which metabolic changes are most important in patients, whether they can be modified safely, and whether doing so changes meaningful clinical outcomes. Even if vitamin B12 itself does not become a therapy, the work could reveal other intervention points in the affected metabolic network.
For rare-disease research, that is a valuable outcome. The study offers a mechanistic link between RNA splicing, metabolism and development, and it turns a broad genetic problem into a more specific set of questions that can be tested. Its strongest conclusion is not that a vitamin has solved Verheij syndrome, but that a potentially actionable pathway has come into view.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com







